{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T16:36:18Z","timestamp":1716482178288},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-lymphoblastic leukemia\/lymphoma (B-ALL) is the most common type of childhood cancer; it also occurs in teenagers and adults, in whom the prognosis is generally less favorable. Therapeutic and molecular advances have substantially improved the treatment for subtypes of B-ALL, such that subclassification by cytogenetic and molecular alterations is critical for risk stratification and management. Novel rearrangements involving ABL1, JAK2, EPO, and other kinases have been identified that may respond to inhibition akin to BCR-ABL1. This diverse group of leukemias has been recognized as a provisional entity in the 2016 revision of the World Health Organization (WHO) Classification of the Hematopoietic Neoplasms as B-lymphoblastic leukemia\/lymphoma, BCR-ABL1\u2013like (Ph-like B-ALL).<\/jats:p><jats:p>Herein, we present cytogenetic and molecular analysis of a case of B-ALL in a 16-year-old Caucasian boy with t(3;9) FOXP1-ABL1 rearrangement and concurrent loss of IKZF1, CDKN2A, and RB1 gene loci, meeting WHO criteria for Ph-like ALL. This case highlights diagnostic, prognostic, and therapeutic considerations of this recently recognized entity.<\/jats:p>","DOI":"10.1093\/labmed\/lmz008","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T20:39:50Z","timestamp":1549571990000},"page":"401-405","source":"Crossref","is-referenced-by-count":3,"title":["BCR-ABL1-like B-Lymphoblastic Leukemia\/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use"],"prefix":"10.1093","volume":"50","author":[{"given":"Ashwini K","family":"Yenamandra","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology & Immunology; Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saara","family":"Kaviany","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics; Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt; Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C","family":"Borinstein","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics; Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt; Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra L","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics; Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt; Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra E","family":"Kovach","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology & Immunology; Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2019101009585358700_CIT0001","author":"Nationwide Children\u2019s"},{"key":"2019101009585358700_CIT0002","first-page":"203","article-title":"B-Lymphoblastic leukemia\/lymphoma with recurrent genetic abnormalities","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Borowitz","year":"2017","edition":"4th ed."},{"issue":"7137","key":"2019101009585358700_CIT0003","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature."},{"issue":"5906","key":"2019101009585358700_CIT0004","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.1164266","article-title":"Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia","volume":"322","author":"Mullighan","year":"2008","journal-title":"Science."},{"issue":"5","key":"2019101009585358700_CIT0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med."},{"issue":"2","key":"2019101009585358700_CIT0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell."},{"issue":"11","key":"2019101009585358700_CIT0007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med."},{"issue":"25","key":"2019101009585358700_CIT0008","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood."},{"issue":"27","key":"2019101009585358700_CIT0009","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"2019101009585358700_CIT0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia."},{"issue":"6","key":"2019101009585358700_CIT0011","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pbc.25327","article-title":"TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP\/PDGFRB translocation","volume":"62","author":"Kobayashi","year":"2015","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2019101009585358700_CIT0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the Type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell."},{"issue":"2","key":"2019101009585358700_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2019101009585358700_CIT0014","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ni1358","article-title":"Foxp1 is an essential transcriptional regulator of B cell development","volume":"7","author":"Hu","year":"2006","journal-title":"Nat Immunol."},{"issue":"2","key":"2019101009585358700_CIT0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.coi.2007.02.002","article-title":"Transcriptional regulation in early B cell development","volume":"19","author":"Fuxa","year":"2007","journal-title":"Curr Opin Immunol."},{"issue":"18","key":"2019101009585358700_CIT0016","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2015-09-666529","article-title":"FOXP1 inhibits plasma cell differentiation","volume":"126","author":"Toellner","year":"2015","journal-title":"Blood."},{"issue":"24","key":"2019101009585358700_CIT0017","first-page":"8820","article-title":"The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p","volume":"61","author":"Banham","year":"2001","journal-title":"Cancer Res."},{"issue":"21","key":"2019101009585358700_CIT0018","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2012-10-462846","article-title":"Downregulation of FOXP1 is required during germinal center B-cell function","volume":"121","author":"Sagardoy","year":"2013","journal-title":"Blood."},{"issue":"10","key":"2019101009585358700_CIT0019","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","article-title":"Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Acute Leukemia Working Party (GIMEMA AL WP)","volume":"114","author":"Iacobucci","year":"2009","journal-title":"Blood."},{"issue":"12","key":"2019101009585358700_CIT0020","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2019101009585358700_CIT0021","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","article-title":"Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia","volume":"2","author":"Tran","year":"2018","journal-title":"Blood Adv."},{"issue":"4","key":"2019101009585358700_CIT0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2015.125336","article-title":"A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis","volume":"101","author":"Francis","year":"2016","journal-title":"Haematologica."},{"issue":"6","key":"2019101009585358700_CIT0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/ajcp\/aqx111","article-title":"Philadelphia chromosome-like mixed-phenotype acute leukemia demonstrating P2RY8-CRLF2 fusion and JAK1 mutation","volume":"148","author":"Choi","year":"2017","journal-title":"Am J Clin Pathol."},{"issue":"4","key":"2019101009585358700_CIT0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","article-title":"CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: a single-institution experience","volume":"147","author":"Konoplev","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"2019101009585358700_CIT0025","article-title":"Fresh incentive to look for Ph-like ALL","author":"Titus","journal-title":"CAP TODAY Online"},{"issue":"2","key":"2019101009585358700_CIT0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-012-0122-5","article-title":"Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments","volume":"7","author":"Iacobucci","year":"2012","journal-title":"Curr Hematol Malig Rep."},{"issue":"26","key":"2019101009585358700_CIT0027","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/50\/4\/401\/30128514\/lmz008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/50\/4\/401\/30128514\/lmz008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T10:19:58Z","timestamp":1573899598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/50\/4\/401\/5425723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmz008","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,4,1]]}}}